Thorac Cardiovasc Surg 2019; 67(S 01): S1-S100
DOI: 10.1055/s-0039-1678763
Oral Presentations
Sunday, February 17, 2019
DGTHG: Langzeitverlauf nach Korrektur angeborener Herzfehler
Georg Thieme Verlag KG Stuttgart · New York

Long-Term Outcome after Mitral Valve Repair in Children Up to the Age of 10 Years

B. Mayr
1   Deutsches Herzzentrum München, Klinik für Herz- und Gefäßchirurgie, München, Germany
2   Department of Cardiovascular Surgery, Insure Institute for Translational Cardiac Surgery, Munich, Germany
,
K. Vitanova
1   Deutsches Herzzentrum München, Klinik für Herz- und Gefäßchirurgie, München, Germany
2   Department of Cardiovascular Surgery, Insure Institute for Translational Cardiac Surgery, Munich, Germany
,
N. Lang
3   Deutsches Herzzentrum München, Klinik für Kinderkardiologie und Angeborene Herzfehler, München, Germany
,
M. Strbad
1   Deutsches Herzzentrum München, Klinik für Herz- und Gefäßchirurgie, München, Germany
2   Department of Cardiovascular Surgery, Insure Institute for Translational Cardiac Surgery, Munich, Germany
,
B. Voss
1   Deutsches Herzzentrum München, Klinik für Herz- und Gefäßchirurgie, München, Germany
,
R. Lange
1   Deutsches Herzzentrum München, Klinik für Herz- und Gefäßchirurgie, München, Germany
2   Department of Cardiovascular Surgery, Insure Institute for Translational Cardiac Surgery, Munich, Germany
,
J. Cleuziou
1   Deutsches Herzzentrum München, Klinik für Herz- und Gefäßchirurgie, München, Germany
2   Department of Cardiovascular Surgery, Insure Institute for Translational Cardiac Surgery, Munich, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
28 January 2019 (online)

 

    Background: Mitral valve (MV) repair in children is challenging due to the complex morphology. The purpose of the study was to show if MV repair is effective in the long term.

    Methods: We reviewed all MV repairs in patients up to the age of 10 years operated between 1975 and 2017. End points of the study were survival after MV repair and freedom from MV replacement. Morphologic and operative risk factors were evaluated for the end points.

    Results: In 50 consecutive patients, a total of 61 MV repairs were performed. Median age at the time of MV repair was 1.5 years (14 days–4.9 years). A congenital malformation of the MV was present in 40 patients (80%), and 20 patients had acquired MV disease. Additional cardiac malformations were present in 38 patients (76%). Indication for MV repair was either mitral regurgitation (MR) in 84% (n = 51), group MR, or mitral stenosis (MS) in 16% (n = 10), group MS. A redo MV repair was necessary in 11 patients (22%) at a median time of 1.4 months (interquartile range [IQR], 0.24–20.7) after initial repair. Survival after MV repair was 87 ± 6 and 77 ± 8% at 5 and 15 years, respectively. Patients with MR showed a better survival than patients with MS at 15 years after MV repair (p = 0.01). MV replacement was necessary in 18% (n = 11/61) after initial repair at a median time of 0.57 years (IQR, 0.05–6.92). Freedom from MV replacement was 82 ± 5 and 69 ± 8 at 5 and 15 years, respectively. There was no significant difference in freedom from MV replacement at 15 years between patients with MR and patients with MS (p = 0.09). Short chordae and operative leaflet/cleft suture were identified as independent risk factors for MV replacement (p = 0.03).

    Conclusion: MV repair in children proves to be an effective therapy with a good long-term survival and durability of the repaired valve. Patients with MS have a worse outcome than patients with MR. Patients with short chordae and the necessity of a leaflet/cleft suture have a higher risk of MV replacement in the long term.


    #

    No conflict of interest has been declared by the author(s).